The eSS rat, a nonobese model of disordered glucose and lipid metabolism and fatty liver

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Daniele, Stella M ^a   Montenegro, Silvana M ^a,b   Tarres, María C ^a,b   Picena, Juan C ^b   Martinez, Stella M ^a,b  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77953457646     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-15     Document Type: Article

References (40)

1. Biochemical mechanism of lipid-induced impairment of glucosestimulated insulin secretion and reversal with a malate analogue. A Boucher D Lu SC Burgess S Telemaque-Potts MV Jensen H Mulder M-Y Wang H Roger RH Unger D Sherry CB Negar, J Biol Chem 2004 279 27263 27271 10.1074/jbc.M401167200 15073188
2. Serum lipoprotein lipase mass: Clinical significance of its measurement. J Kobayashi A Nohara MA Kawashiri A Inazu J Koizumi K Nakajima H Mabuchi, Clin Chim Acta 2007 378 7 12 10.1016/j.cca.2006.12.003 17223095
3. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. AJ Krentz, Diabetes Obes Metab 2003 5 Suppl 1 19 27 10.1046/j.1462-8902.2003.0310.x (Pubitemid 37483614)
4. The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13). KJ van Hateren GW Landman N Kleefstra SJ Logtenberg KH Groenier AM Kamper ST Houweling HJ Bilo, PLoS One 2009 4 8464 10.1371/journal.pone.0008464 20041116
5. eSS rat, an animal model for the study of spontaneous non-insulin-dependent diabetes. SM Martinez MC Tarres JC Picena SM Montenegro JJ Gagliardino CL Gomez Dumm AE D'Ottavio A Naves SL Rabasa, Lessons from Animal Diabetes IV London: Smith-Gordon, Eleazar Shafrir, 1 1993 75 90
6. Modificaciones dinmicas en los islotes de Langerhans de dos líneas de ratas espontneamente diabéticas: eSS y eSMT. JC Picena SM Montenegro MC Tarrés SM Martínez, Medicina (Buenos Aires) 2007 67 331 340
7. Early lipid alterations in spontaneously diabetic rats. IN de Gomez Dumm S Montenegro MC Tarres SM Martinez RA Igal, Acta Physiol Pharmacol Ther Latinoam 1998 48 228 234 9914813
8. Hepatic 9, 6 and 5 Desaturations in the Non-Insulin Dependent Diabetic Mellitus eSS Rats. M Montanaro OJ Rimoldi RA Igal S Montenegro MC Tarres SM Martinez RR Brenner, Lipids 2003 38 827 832 10.1007/s11745-003-1132-7 14577661
9. Hígado graso no alcohálico en ratas machos de una línea con diabetes genética. SM Daniele JC Picena SM Montenegro MC Tarres SM Martinez, Rev Electron Biomed 2007 3 29 39
10. Lipoproteínas de densidad intermedia y lipasa heptica en mujeres post-menopusicas. H Halperin G Berg L Aisemberg R Wikinski, Medicina (Buenos Aires) 1992 52 213 219
11. Pathogenesis of NIDDM. A balanced overview. RA DeFronzo R Bonadonna E Ferrannini, Diabetes Care 1992 15 318 68 10.2337/diacare.15.3.318 1532777
12. International Lipid Information Bureau (ILIB), LipidDigest Latinoamerica 2002 8 2 8
13. Dyslipidemia in type 2 diabetes: epidemiology and biochemistry. J Valabhji RS Elkeles, Br J Diabetes Vasc Dis 2003 3 184 189 10.1177/ 14746514030030030501
14. Statins and diabetes. R Carmena DJ Betteridge, Semin Vasc Med 2004 4 321 32 10.1055/s-2004-869589 15861314
15. Classification of hyperlipidemias and hyperlipoproteinemias. JL Beaumont LA Carlson GR Cooper Z Fejfar DS Fredrickson T Strasser, Bull WHO 1970 43 891 908 4930042
16. How good a marker is insulin level for insulin resistance? M Laakso, Am J Epidemiol 1993 137 959 965 8317453
17. Insulin resistance: definition and consequences. HE Lebovitz, Exp Clin Endocrinol Diabetes 2001 109 Suppl 2 135 148 10.1055/s-2001-18576 11409294
18. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. AJ Krentz, Diabetes Obes Metab 2003 5 Suppl 1 19 27 10.1046/j.1462-8902.2003.0310.x (Pubitemid 37483614)
19. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. AT Santomauro G Boden ME Silva DM Rocha RF Santos MJ Ursich PG Strassmann BL Wajchenberg, Diabetes 1999 48 1836 1841 10.2337/diabetes.48.9.1836 10480616
20. Saturated and unsaturated (including arachidonic acid) non-esterified fatty acid modulation of insulin secretion from pancreatic beta-cells. D Keane P Newsholme, Biochem Soc Trans 2008 36 955 958 10.1042/BST0360955 18793168
21. Life and death decisions of the pancreatic beta-cell: the role of fatty acids. P Newsholme D Keane HJ Welters NG Morgan, Clin Sci (Lond) 2007 112 27 42 10.1042/CS20060115 17132138
22. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. K Kusi, Clin Liver Dis 2009 13 545 63 10.1016/j.cld.2009.07.009 19818304
23. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. HB Holt SH Wild PJ Wood J Zhang AA Dareka K Dewbury RB Poole RIG Holt DI Phillips CD Byrne, Diabetologia 2006 49 141 148 10.1007/s00125-005-0070-x 16323001
24. Liver fat and lipid oxidation in humans. A Kotronen A Seppälä-Lindroos S Vehkavaara R Bergholm KN Frayn BA Fielding H Yki-Järvinen, Liver Int 2009 29 1439 1446 10.1111/j.1478-3231.2009.02076.x 19602132
25. Oral taurine but not N-acetylcysteine ameliorates NEFA-induced impairment in insulin sensitivity and beta cell function in obese and overweight, non-diabetic men. C Xiao A Giacca GF Lewis, Diabetologia 2008 51 139 146 10.1007/s00125-007-0859-x 18026714
26. Influence of Hepatic steatosis (Fatty Liver) on severity and composition of dyslipidemia in Type 2 Diabetes. FGS Toledo AD Sniderman DE Kelley, Diabetes Care 2006 29 1845 1850 10.2337/dc06-0455 16873790
27. Fatty liver, insulin resistance, and dyslipidemia. M Adiels MR Taskinen J Boren, Curr Diab Rep 2008 8 60 64 10.1007/s11892-008-0011-4 18367000
28. Regulation of plasma triglycerides in insulin resistance and diabetes. HN Ginsberg YL Zhang A Hernandez-Ono, Arch Med Res 2005 36 232 240 10.1016/j.arcmed.2005.01.005 15925013
29. Hepatic Very Low Density Lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. C Taghibiglou F Rashid-Kolvear SC Van Iderstine H Le-Tien IG Fantus GF Lewis K Adeli, J Biol Chem 2002 277 793 803 10.1074/jbc.M106737200 11598116
30. Hepatic lipase: Friend or foe and under what circumstances? H Jansen, Curr Atheroscler Rep 2004 6 343 347 10.1007/s11883-004-0044-3 15296699
31. The extended postprandial phase in diabetes. D Owens, Biochem Soc Trans 2003 31 1085 1089 10.1042/BST0311085 14505485
32. New Insights into the Regulation of HDL Metabolism and Reverse Cholesterol Transport. GF Lewis DJ Rader, Circulation Res 2005 96 1221 1232 10.1161/01.RES.0000170946.56981.5c 15976321
33. When HDL gets fat (Editorial). RJ Brown DJ Rader, Circ Res 2008 103 131 132 10.1161/CIRCRESAHA.108.180638 18635830
34. Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis (Brief Review). S Santamarina-Fojo H Gonzalez-Navarro L Freeman E Wagner Z Nong, Arterioscler Thromb Vasc Biol 2004 24 1750 1754 10.1161/01.ATV.0000140818.00570.2d 15284087
35. Opposite contributions of trunk and leg fat mass with plasma lipase activities: The Hoorn Study. G Bos MB Snijder G Nijpel M Jacqueline J Dekker CDA Stehouwer LM Bouter RJ Heine H Jansen, Obes Res 2005 13 1817 1823 10.1038/oby.2005.221 16286530
36. Heritable, diet-induced hyperlipidemia in California mice (Peromyscus californicus) is due to increased hepatic secretion of very low density lipoprotein triacylglycerol. L Krugner-Higby GS Shelness A Holler, Comp Med 2006 56 468 475 17219776
37. Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. H Mabuchi A Inazu, Future Lipidol 2007 2 1 4 10.2217/17460875.2.1.1 (Pubitemid 46805483)
38. Estudio anatomopatolágico del pncreas y del rĩán de la rata diabética eSMT. Su comparacián con la rata diabética eSS. JC Picena, Tesis doctoral Facultad de Ciencias Médicas. Universidad Nacional de Rosario, Argentina 2005
39. Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL. Z Zak L Lagrost Th Gautier D Masson V Deckert L Linda Duverneuil J-P Pais de Barros N Le Guern L Dumont M Schneider V Risson P Moulin D Autran G Brooker J Sassard A Bataillard, J Lipid Res 2002 43 2164 2171 10.1194/jlr.M200253-JLR200 12454279
40. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. SE Borggreve R De Vries RP Dullaart, Eur J Clin Invest 2003 33 1051 1069 10.1111/j.1365-2362.2003.01263.x 14636288